GLP-1 lawsuits

What each label says

Eight products are named in the gastrointestinal-injury litigation, across two manufacturers and four molecules. Their labels do not say the same things as each other, and the differences are worth more than any summary of the claims.

A warning and a report are not the same thing

Every label carrying these entries also says the reports come from a population of uncertain size, and that a causal relationship often cannot be established.

This is the distinction the whole subject turns on, and almost nothing written about GLP-1 litigation preserves it.

A warning sits in section 5 of a label. It is wording the FDA has reviewed and approved, and it is there because the agency concluded prescribers need to act on it. The gastroparesis entries in the table above are of this kind — and read carefully, most of them say the product is not recommended in patients who already have severe gastroparesis. That is a caution about who should be given the drug. It is not a statement that the drug causes the condition, and the labels do not make that second claim.

A postmarketing report is a different kind of entry entirely. It records that people taking the drug have reported something, gathered from voluntary reports after approval. Every label carrying such a section says so explicitly: the reports come from a population of uncertain size, their frequency cannot be reliably estimated, and a causal relationship to the drug often cannot be established. Ileus and intestinal obstruction appear here rather than as warnings.

So “it is on the label” can mean two very different things, and a page that does not tell you which one it means is not telling you much.

Vision-loss litigation and the separate regulatory evidence

The Eastern District of Pennsylvania maintains MDL 3163 for GLP-1 RA NAION product-liability claims. Checked 22 September 2026. Consolidation coordinates litigation; it does not establish that a medicine caused an individual injury or that a manufacturer is liable.

NAION affects the optic nerve and is distinct from diabetic retinopathy. EMA concluded in June 2025 that it is a very rare adverse effect of semaglutide, recommending EU product-information changes. That finding is separate from US court allegations and the older US label extraction in our table. An absent term in that extraction is not evidence of no risk or a statement about every current label.

Sudden vision loss or rapidly worsening eyesight needs immediate medical assessment. Read the clinical vision-loss guidance; a lawsuit page cannot diagnose an eye problem.

One label is much older than the others

Wegovy is the outlier in that table, and the reason is worth understanding before reading anything into it. The newest Wegovy label held in FDA’s openFDA archive is dated 2024-04-23. Every other product in the set has been updated since, several of them this year.

On that older label, the gastroparesis caution and the aspiration warning do not appear. Both appear on Ozempic’s label — which is the same molecule, semaglutide, from the same manufacturer, sold under a different name for a different approved use.

The honest reading is narrow. This is a fact about the archive we can check, not proof about the leaflet in a current box: openFDA can lag, and a label absent from it is not a label that does not exist. What can be said is that the most recent Wegovy labelling FDA publishes in that archive predates warnings its own molecule carries under another brand, and anyone comparing the two products on their labels should know the dates are two years apart.

What this page does not do

It does not tell you how many cases have been filed. Docket counts are the number every competing page leads with, and every version of it we could find traces back to a law firm’s own summary rather than to a court. This site’s standard is that a figure comes from a named, dated primary source, so the number is absent rather than borrowed.

It does not tell you whether you have a claim, and it will not connect you to anybody who says they can answer that for free. How this site earns is published in full: flat referral fees from telehealth providers in an unranked directory, and nothing whatever from legal referrals. That is worth saying on this page specifically, because legal lead generation is the business model of nearly everything else ranking for this question.

Questions people ask

This page is general education, not medical advice. Talk to your own healthcare provider about your situation before starting, stopping, or changing any medication.